CLL Drug Pipeline: BTK Inhibitors — PatSnap Eureka
CLL Pipeline: Non-Covalent BTK Inhibitors & Venetoclax Combinations
Chronic lymphocytic leukemia affects approximately 904,000 people globally. Explore the IP landscape of BTK inhibitor combinations, venetoclax-based regimens, HDAC co-targeting, and biomarker-guided treatment selection — powered by PatSnap Eureka.
BCR Signaling, BCL-2 Overexpression, and the CLL Molecular Landscape
Chronic lymphocytic leukemia (CLL) remains the most prevalent adult leukemia in the Western world. Retrieved results consistently identify CLL as a B-cell malignancy characterized by aberrant BCR signaling, anti-apoptotic BCL-2 overexpression, and PI3K/AKT pathway dysregulation. Understanding these molecular drivers is foundational for evaluating the IP landscape around combination therapies.
BTK is the most patent-active CLL target in this dataset. Central to BCR signaling in malignant B cells, it is targeted by both covalent agents such as ibrutinib and next-generation inhibitors including zanubrutinib. Patent filings from Pharmacyclics LLC, Acetylon Pharmaceuticals, and the Board of Trustees of Leland Stanford Junior University all reference BTK as the primary kinase target in CLL/SLL.
BCL-2 overexpression drives apoptotic resistance in CLL cells. Venetoclax, a selective BCL-2 inhibitor, is referenced in clinical literature as demonstrating activity in relapsed/refractory CLL patients who had progressed on multiple BCR pathway inhibitors. Navitoclax (BCL-2/BCL-XL dual inhibitor) and AZD5991 (MCL-1 inhibitor) also appear in Broad Institute treatment selection patents as agents for specific CLL molecular subtypes.
Emerging targets include BRD9, an epigenetic reader aberrantly overexpressed in CLL cells identified in a 2022 Chinese patent filing, and HDAC6, which plays a mechanistic role in BCR signaling suppression when combined with BTK inhibitors. The National Institutes of Health and academic institutions including Ohio State University Research Foundation have further characterized TCL1 and NF-κB as co-therapeutic targets in B-CLL.
Six Active CLL Combination Strategies in the Patent Landscape
From covalent BTK inhibitor backbones to precision-matched epigenetic combinations, the CLL IP landscape spans clinical and preclinical stages across multiple assignee organizations.
Covalent BTK Inhibitors (Ibrutinib-Class)
The most extensively cited therapeutic modality in this dataset. Pharmacyclics LLC patent filings cover ibrutinib-based combination regimens — BTK inhibitor + TLR inhibitor and BTK inhibitor + anti-CD20 agent — across AU, EP, CA, WO, HK, MX, CN, TW jurisdictions (2016–2018). Ibrutinib achieves durable responses in CLL but rarely achieves undetectable minimal residual disease (uMRD) as monotherapy, motivating next-generation BTK inhibitor research.
Pharmacyclics LLC · 9 jurisdictionsBCL-2 Inhibition: Venetoclax
Venetoclax is cited as a clinically active single agent in relapsed/refractory CLL patients who had progressed on more than one BCR pathway inhibitor. The Broad Institute's treatment selection patents (2022–2025) explicitly list venetoclax and navitoclax as agents matched to specific CLL expression subtypes. BRD9 inhibition (I-BRD9) + venetoclax demonstrated synergistic pro-apoptotic effects in primary CLL cells in a 2022 Chinese patent filing.
AbbVie · Broad Institute · ShandongHDAC Inhibitor + BTK Inhibitor Combinations
Acetylon Pharmaceuticals and H. Lee Moffitt Cancer Center patents disclose HDAC6-selective inhibitor combinations with ibrutinib for CLL. Mechanistic claims include suppression of CLL cell IL-10 expression, inhibition of BCR signaling, reduction of circulating lymphocyte counts, and prevention of ibrutinib resistance. The 2015 Sampath filing specifically claims prevention and reversal of ibrutinib resistance using abexinostat + ibrutinib.
Acetylon · Moffitt · 2015–2024PI3K Pathway Inhibitors
Bayer Pharma AG filed an extensive portfolio of copanlisib (PI3Kα/δ inhibitor) biomarker patents across more than 10 jurisdictions (WO, US, EP, CA, AU, SG, MX, CN, CL, TN, 2017–2020), covering stratification of CLL and NHL patients by BCR, PI3K, NFkB, IL6, and stromal pathway gene expression. TG Therapeutics filed patents combining PI3Kδ inhibitor TGR-1202 + anti-CD20 antibody + anti-PD-1/PD-L1 antibody for hematologic malignancies including CLL.
Bayer Pharma AG · TG TherapeuticsBiomarker-Guided Treatment Selection
The Broad Institute filed two substantive CLL treatment selection patents (WO 2022, WO/US 2023–2025), cataloging gene expression subtypes (EC-m3, EC-u2, M-CLL, U-CLL) and matching them to specific targeted agents including ibrutinib, venetoclax, navitoclax, zanubrutinib, A-1331852, AZD5991, voruciclib, and onalespib. F. Hoffmann-La Roche AG / Genentech filed CLL biomarker patents describing miRNA151-3p, miRNA409-3p, PTK2, and PI3K as predictive biomarkers.
Broad Institute · Roche/Genentech · NIH CA206978BRD9 Epigenetic + Venetoclax Combinations
BRD9 is identified as an epigenetic reader aberrantly overexpressed in CLL. The Shandong First Medical University (CN, 2022) patent demonstrates that BRD9 expression is an independent prognostic factor, with BRD9 inhibition showing synergy with venetoclax in primary CLL cells. This represents a novel resistance mechanism target and a co-target opportunity for investors evaluating CLL resistance platforms.
Shandong First Medical University · CN 2022CLL IP Landscape: Key Data Points
Patent activity, development stage distribution, and assignee jurisdiction coverage derived from PatSnap Eureka dataset analysis.
Key Assignee Patent Filing Jurisdictions
Bayer Pharma AG leads jurisdiction breadth with 10+ filings; Pharmacyclics LLC covers 9 key markets including AU, EP, CA, WO, HK, MX, CN, TW, US.
CLL Combination Strategies by Development Stage
Two modalities have reached clinical stage (venetoclax, covalent BTK inhibitors); two are translational; two remain preclinical in this dataset.
Patent Filing Activity by Year (Key CLL Filings)
CLL combination patent activity spans 2012–2025, with concentrated filings from Pharmacyclics (2016–2018) and Broad Institute precision oncology patents emerging 2022–2025.
Emerging CLL Combination Directions
Six active combination directions identified in this dataset, ranging from BTK+BCL-2 pairings to triple immunotherapy combinations and precision-matched subtype algorithms.
Key Organizations & Clinical Signals in the CLL Pipeline
Assess freedom-to-operate for CLL combination regimens
PatSnap Eureka maps active, lapsed, and pending IP across all CLL modalities and jurisdictions.
IP Strategy Signals for CLL Drug Developers
Key strategic findings derived from patent and literature analysis via PatSnap Eureka — for IP strategists, R&D teams, and investors in the CLL space.
Non-Covalent BTK Inhibitor IP Gap
The non-covalent/next-generation BTK inhibitor space (zanubrutinib, tirabrutinib) is represented in this dataset primarily through clinical literature and treatment selection patents, rather than dedicated combination-IP filings. Drug developers pursuing non-covalent BTK inhibitor + venetoclax combinations should assess whether current IP coverage from Pharmacyclics/AbbVie adequately addresses non-covalent inhibitor scaffolds or leaves FTO opportunities.
Broad Institute Precision Oncology IP Risk
The Broad Institute's CLL subtype-to-agent matching patents (WO 2022, US 2023/2025) could become critical enabling IP for clinical trial design. IP strategists evaluating precision oncology programs in CLL should assess freedom to operate relative to these biomarker selection claims, particularly for trials enrolling U-CLL or M-CLL subtypes with venetoclax or zanubrutinib.
CLL Drug Pipeline: BTK Inhibitors & Venetoclax — key questions answered
BTK (Bruton's Tyrosine Kinase) is the most patent-active CLL target in this dataset. Pharmacyclics LLC's filings cover ibrutinib-based combination regimens across AU, EP, CA, WO, HK, MX, CN, TW, and US jurisdictions, including BTK inhibitor + TLR inhibitor and BTK inhibitor + anti-CD20 agent combinations.
Venetoclax (BCL-2 inhibitor) is cited as a clinically active single agent in relapsed/refractory CLL patients who had progressed on more than one BCR pathway inhibitor. The AbbVie Inc.-associated clinical literature record (2018) describes venetoclax's activity in this setting and contextualizes its role post-BTKi failure.
The Broad Institute, Inc. filed CLL treatment selection patents (2022–2025) cataloging gene expression subtypes (EC-m3, EC-u2, M-CLL, U-CLL) and matching them to specific targeted agents — including ibrutinib, venetoclax, navitoclax, zanubrutinib, A-1331852, AZD5991, voruciclib, and onalespib.
Acetylon Pharmaceuticals and H. Lee Moffitt Cancer Center patents describe HDAC6-selective inhibitors as capable of preventing ibrutinib resistance. The 2015 Sampath filing specifically claims prevention and reversal of ibrutinib resistance using abexinostat + ibrutinib. Mechanistic claims include suppression of CLL cell IL-10 expression, inhibition of BCR signaling, and reduction of circulating lymphocyte counts.
BRD9 is identified as an epigenetic reader aberrantly overexpressed in CLL. BRD9 expression was found to be an independent prognostic factor, with BRD9 inhibition showing synergy with venetoclax in primary CLL cells. The Shandong First Medical University (CN, 2022) patent demonstrates that I-BRD9 + venetoclax demonstrated synergistic pro-apoptotic effects in primary CLL cells.
Pharmacyclics LLC (AbbVie subsidiary) dominates the BTK inhibitor combination patent space with filings across AU, EP, CA, WO, HK, MX, CN, TW, and US. The Broad Institute leads precision oncology frameworks. Acetylon Pharmaceuticals and H. Lee Moffitt Cancer Center co-own the HDAC + BTK inhibitor platform. Bayer Pharma AG holds an extensive copanlisib biomarker portfolio across more than 10 jurisdictions.
Still have questions about the CLL pipeline? Let PatSnap Eureka search patents and literature for you.
Ask Eureka About CLL Drug IPAccelerate Your CLL Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to navigate complex drug pipelines, assess freedom-to-operate, and identify emerging combination therapy opportunities in oncology.
References
- Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor — AbbVie Inc., 2018
- Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia — University of Cologne / German CLL Study Group, 2022
- TLR inhibitor and Bruton's tyrosine kinase inhibitor combinations — Pharmacyclics LLC, 2017, AU
- BTK inhibitor combinations and dosing regimen — Pharmacyclics LLC, 2017, EP
- HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia — Acetylon Pharmaceuticals, Inc., 2017, WO
- HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia — H. Lee Moffitt Cancer Center and Research Institute, Inc., 2019, US
- HDAC inhibitor and BTK inhibitor combinations — Sampath, Deepa, 2015, WO
- Compositions, panels, and methods for characterizing chronic lymphocytic leukemia — The Broad Institute, Inc., 2022, WO
- Methods for treatment selection for chronic lymphocytic leukemia (CLL) — The Broad Institute, Inc., 2025, US
- Copanlisib biomarkers — Bayer Pharma AG, 2017, WO
- Combination of an Anti-CD20 antibody, PI3 kinase-delta inhibitor, and Anti-PD-1 or Anti-PD-L1 antibody for treating hematological cancers — TG Therapeutics, Inc., 2019, MX
- BRD9 application in CLL diagnosis and treatment — Shandong First Medical University Affiliated Provincial Hospital, 2022, CN
- Chronic lymphocytic leukemia (CLL) biomarkers — F. Hoffmann-La Roche AG, 2012, WO
- National Institutes of Health (NIH) — NIH Grant CA206978 supporting Broad Institute CLL research
- U.S. Food and Drug Administration (FDA) — Venetoclax approval context referenced in AbbVie 2018 clinical paper
- National Cancer Institute (NCI) — CLL disease background and BCR pathway context
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.